Bookmark
Forward
QuickView for ximelagatran (compound)
PubChem
| Name: | ximelagatran |
|---|---|
| PubChem Compound ID: | 9574101 |
| Molecular formula: | C24H35N5O5 |
| Molecular weight: | 473.565 g/mol |
| Synonyms: |
D01981; Exanta; H-376/95; 192939-46-1; Ximelagatran; H 376-95; Ethyl (((1R)-1-cyclohexyl-2-((2S)-2-((4-(hydroxycarbamimidoyl)benzyl)carbamoyl)azetidin-1-yl-2-oxoethyl)amino)acetate; Glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-, ethyl ester; H 376/95; H 37695.
show more » |
DrugBank
Identification
| Name: | ximelagatran |
|---|---|
| Name (isomeric): | DB04898 |
| Drug Type: | small molecule |
| Synonyms: |
H 376/95
|
| Brand: | Exarta, Exanta |
| Category: | Anticoagulants, Antithrombotic Agents |
| CAS number: | 192939-46-1 |
Pharmacology
| Indication: | For the treatment of acute deep vein thrombosis. |
|---|---|
| Mechanism of Action: | Ximelagatran was the first member of the drug class of direct thrombin inhibitors that can be taken orally. It acts solely by inhibiting the actions of thrombin. Ximelagatran is a prodrug, being converted in vivo to the active agent melagatran. |
| Absorption: | Rapidly absorbed by the small intestine with an oral bioavailability of 20%. |
| Biotransformation: | Hepatic. Ximelagatran is a prodrug, being converted in vivo to the active agent melagatran. This conversion takes place in the liver and many other tissues through dealkylation and dehydroxylation (replacing the ethyl and hydroxyl groups with hydrogen). |
| Half Life: | 3-5 hours |
| Toxicity: | Hepatotoxicity (liver damage) was reported during trials. |
| Affected organisms: | Humans and other mammals |
Targets
Enzymes
